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ABSTRACT 
Objective: To investigate the presence of variants in the TAC3 and TACR3 genes, which encode 
NKB and its receptor (NK3R), respectively, in a large cohort of patients with idiopathic central 
pubertal disorders. Subjects and methods: Two hundred and thirty seven patients were studied: 
114 with central precocious puberty (CPP), 73 with normosmic isolated hypogonadotropic hy-
pogonadism (IHH), and 50 with constitutional delay of growth and puberty (CDGP). The control 
group consisted of 150 Brazilian individuals with normal pubertal development. Genomic DNA 
was extracted from peripheral blood and the entire coding region of both TAC3 and TACR3 ge-
nes were amplified and automatically sequenced. Results: We identified one variant (p.A63P) in 
NKB and four variants, p.G18D, p.L58L (c.172C>T), p.W275* and p.A449S in NK3R, which were 
absent in the control group. The p.A63P variant was identified in a girl with CPP, and p.A449S 
in a girl with CDGP. The known p.G18D, p.L58L, and p.W275* variants were identified in three 
unrelated males with normosmic IHH. Conclusion: Rare variants in the TAC3 and TACR3 genes 
were identified in patients with central pubertal disorders. Loss-of-function variants of TACR3 
were associated with the normosmic IHH phenotype. Arq Bras Endocrinol Metab. 2012;56(9):646-52
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RESUMO
Objetivo: Investigar a presença de variantes nos genes TAC3 e TACR3, os quais codificam a NKB e 
seu receptor (NK3R), respectivamente, em uma coorte de pacientes com distúrbios puberais cen-
trais idiopáticos. Sujeitos e métodos: Duzentos e trinta e sete pacientes foram estudados: 114 com 
puberdade precoce central (PPC), 73 com hipogonadismo hipogonadotrófico isolado normósmico 
(HHI) e 50 com retardo constitucional do crescimento e desenvolvimento (RCCD). O grupo con-
trole consistiu de 150 indivíduos brasileiros que apresentaram desenvolvimento puberal normal. 
O DNA genômico foi extraído de sangue periférico, e as regiões codificadoras dos genes TAC3 e 
TACR3 foram amplificadas e sequenciadas automaticamente. Resultados: Uma variante (p.A63P) 
foi identificada na NKB, e quatro variantes, p.G18D, p.L58L (c.172C>T), p.W275X e p.A449S, foram 
identificadas no NK3R, as quais foram ausentes no grupo controle. A variante p.A63P foi identifi-
cada em uma menina com PPC, e a variante p.A449S, em uma menina com RCCD. As variantes 
previamente descritas, p.G18D, p.L58L e p.W275X, foram identificadas em três indivíduos com 
HHI normósmico do sexo masculino não relacionados. Conclusão: Variantes raras nos genes TAC3 
e TACR3 foram identificadas em pacientes com distúrbios puberais centrais idiopáticos. Mutações 
de perda de função no gene TACR3 foram associadas com o fenótipo de HHI normósmico. Arq Bras 
Endocrinol Metab. 2012;56(9):646-52
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INTRODUCTION
N eurokinin B (NKB) is a member of the mam-malian tachykinin family of peptides, classified as 
neurotransmitters that include substance P, neurokinin 
A, neurokinin B, as well as neuropeptide K, neuropep-
tide γ, and hemokinin-1 (1). Recent advances in the 
field of tachykinins have considerably increased interest 
in this peptide family (2). Anatomical, neurochemical, 
and pharmacological evidence suggest that these pep-
tides could play a role as mediators of nonadrenergic 
and noncholinergic excitatory neurotransmission (3-5). 
Tachykinins interact with three distinct types of recep-
tors termed NK1R, NK2R, and NK3R, which are pref-
erentially activated by SP, NKA, and NKB, respectively 
(2). In humans, NKB and its receptor are encoded by 
the TAC3 and TACR3 genes, respectively (1,6). 
The neurokinin B system has recently been impli-
cated in the regulation of the human reproductive axis, 
following the identification of inactivating mutations in 
TAC3 and TACR3 genes in patients with normosmic 
isolated hypogonadotropic hypogonadism (IHH) (7). 
In a seminal study, Topaloglu and cols. (7) identified a 
critical role for NKB in human reproduction using ge-
nome-wide SNP analysis in nine inbred Turkish families 
with multiple members affected with normosmic IHH 
(7). In this study, rare missense variants in the TAC3 
and TACR3 genes were described in four of these 
families with normosmic IHH (7). This first report im-
plicated NKB signaling as an essential component for 
the onset of puberty and the control of gonadotropin 
secretion in humans (1). To date, approximately 50 in-
dividuals with TAC3 and TACR3 mutations have been 
described, with a worldwide distribution and a diverse 
racial mix (7-12). Recently, we reported that mutations 
in the NKB system occurred in more than 5% of a nor-
mosmic IHH population (10). 
The mechanism whereby the NKB system exerts its 
effects on the central neuroendocrine control of human 
reproduction remains unknown (13). Several lines of ev-
idence suggest that neurokinin B might have a role as a 
regulator of GnRH secretion (14). Furthermore, animal 
studies demonstrated that Kiss1 neurons of the arcuate 
nucleus coexpress NKB and dynorphin (Dyn) (14-16). 
These neurons were also confirmed to coexpress NK3R, 
suggesting a role in coordinating the activity of NKB/
Dyn/Kisspeptin neurons of the arcuate nucleus. 
Kisspeptin receptor and its ligand, kisspeptin, have 
been considered as major gatekeepers of puberty on-
set (17). Teles and cols. (18) reported a first activating 
mutation in the kisspeptin receptor (p.R386P) in an 
adopted Brazilian girl with central precocious puberty 
(18). More recently, Silveira and cols. (19) identified 
one new rare variant in the kisspeptin (p.P74S) in one 
boy with sporadic central precocious puberty. There-
fore, it is also reasonable to hypothesize that gain-of-
function mutation in TACR3, encoding a G protein-
coupled receptor, might be identified in children with 
central precocious puberty (13). In this study, we inves-
tigated the presence of activating variants in the TAC3 
and TACR3 genes in a large group of patients with id-
iopathic central precocious puberty. We also searched 
for inactivating variants in additional patients with nor-
mosmic IHH, as well as in patients with constitutional 
delay of growth and puberty.
MATERIALS AND METHODS 
Patients 
Two hundred and thirty seven patients with central 
pubertal disorders were studied: 114 with central pre-
cocious puberty (CPP), 73 with normosmic isolated 
hypogonadotropic hypogonadism (IHH), and 50 with 
constitutional delay of growth and puberty (CDGP) 
(Table 1). Sixty IHH patients were previously repor-
ted (10). All patients were evaluated at Universidade 
de Sao Paulo (USP), except 26 North American pa-
tients with CPP who were referred to Harvard Medical 
School. Informed written consent was obtained from 
all patients, and the study was approved by the Ethics 
Committee of the Hospital das Clinicas, Universida-
de de Sao Paulo. FGFR1, FGF8, GNRH1, GNRHR, 
KISS1R, KISS1, PROK2, and PROKR2 genes were 
previously studied in the cohort of patients with IHH. 
In addition, GNRHR, KISS1R, KISS1, and LIN28B 
genes were previously studied in Brazilian patients with 
CPP. The control population consisted of 150 healthy 
Brazilian individuals of both genders with normal pu-
bertal development.
The diagnosis of central precocious puberty was 
based on the following criteria: puberty onset before 
eight years of age in girls and nine years of age in boys, 
pubertal LH levels (basal and/or after an acute GnRH 
stimulation test), and normal central nervous system 
magnetic resonance imaging (MRI). 
The diagnosis of normosmic IHH was based on 
incomplete or absent pubertal development after 18 
years, prepubertal or low testosterone or estradiol levels 
for the age, low or normal basal gonadotropin levels but 
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Table 1. Clinical features at the time of diagnosis of the Brazilian patients 
with idiopathic central pubertal disorders
Disorder CPP IHH CDPG
Number of patients 114 73 50
Gender 107 girls/7 boys 26 women/47 men 11 girls/39 boys
Chronological age 5.2 ± 2.1 23.8 ± 8.1 14.8 ± 1.4 
Bone age 9.7 ± 2.5 14.5 ± 2.2 11.8 ± 1 
Basal LH (IU/L) 1.5 ± 1.7 1.4 ± 2.1 1.0 ± 0.6 
Peak LH (IU/L) 17.9 ± 13.6 - -
FSH (IU/L) 3.5 ± 1.9 1.9 ± 1.8 2.0 ± 1.1
Testosterone (ng/dL)¹ 280.0 ± 235.0 45.0 ± 33.0 65.0 ± 71.0
Estradiol (pg/mL)² 56.6 ± 19.8 37.0 ± 23.1 48.0 ± 41.0
% Familial 19.4%¹ 16.4% 22% 
CPP: central precocious puberty; IHH: isolated hypogonadotropic hypogonadism; CDGP: 
constitutional delay of growth and puberty. The complete hormonal data were available for 76 
Brazilian patients with CPP (72 girls and 4 boys), 59 patients with normosmic IHH (21 women 
and 38 men), and 50 patients with CDGP (11 girls and 39 boys).¹ Hormonal analyses of male 
patients.² Hormonal analyses of female patients. Peak LH: LH after acute GnRH stimulation 
test. IFMA (Immunofluorometric method). Reference ranges (IFMA): FSH (prepubertal girls 
and boys ≤ 3.2 IU/L; adult males 2.9-7.8 IU/L and adult women (follicular phase) 2.4-9.3 
IU/L); LH (prepubertal girls and boys ≤ 0.6 IU/L; adult males 1.0-8.4 IU/L and adult females 
(follicular phase) 2.2-6.8 U/L); Testosterone (prepubertal boys < 14 ng/dL and adult males 
200-950 ng/dL); Estradiol (prepubertal girls < 21 pg/mL and adult women (follicular phase) 
22-215 pg/mL).
otherwise normal pituitary function, and normal hypo-
thalamic-pituitary imaging. The diagnosis of CDGP 
was based on lack of breast development (Tanner stage 
2) by the age of 13 and absent menarche by the age of 
15 years in girls, and testicular volume < 4.0 mL by the 
age of 14 years in boys, absence of other identifiable 
causes of delayed puberty, delayed bone age, as well 
as spontaneous and complete achievement of pubertal 
development by age 18 years, during follow-up. 
DNA analysis
Genomic DNA was extracted from peripheral blood 
leukocytes using standard procedures. The entire co-
ding regions and the intron-exon junctions of TAC3 
(GenBank accession number – MIM162330) and 
TACR3 (GenBank accession number – MIM162332) 
genes were amplified by polymerase chain reaction 
using specific primers, and were automatically sequen-
ced (Table 2).
Amplification reactions were performed in a final 
volume of 25 µL containing 200 ng genomic DNA, 
0.2 mM dNTPs, 1.5 mM PCRx Enhancer Solution 
(Invitrogen), 0.6 pmol each primer, 1X PCR buffer, 
and 1U Go Taq DNA polymerase (Promega, Madison, 
WI), and were carried out for 35 cycles: denaturation 
at 95ºC for 30 s, annealing at 55-56ºC for 30 s, exten-
Table 2. Oligonucleotide sequences and annealing temperature (ºC) of 
TAC3 and TACR3 genes PCR
Gene Exon Oligonucleotide sequence Annealing temp (ºC)
TACR3 1 1F   5´CAGGGATTGCAGTATCTTTC 3´
1R   5´CCTCCTTTCAGCAAAAATTC3´
55
2 2F   5´GCCATGATTACCATTCTACG3´
2R   5´ACTTATTGACCACACACAAATC3´
56
3 3F   5´CAACTGGCAGCATTTGAAAC3´
3R   5´gattacagtatgtggacagcagc3´
56
4 4F   5´CTGTCCGTATATTGCTTCACC3´
4R   5´AAGCCTGTGCCTCTCTCAG3´
55
5 5F   5´TGACATAAATTCTAAGAGTCTGG3´
5R   5´CTTTCTCAATTTGACCATAGC3´
55
TAC3 2 2F   5´CAAGCTGCTGGTAATGAATG3´
2R   5´AAATGCCCTCTGACGGAC3´
55
3 and 4 34F   5´GATTCAGGATGGGCTCAGG3´
34R   5´GGGAGCTGGCATATTGTTTG3´
55
5 and 6 56F   5´GAACAGAGACCAGAAACCCAGTC3´
56R   5´TTTAATACCTGTAGCATGGGAGGAA3´
56
F: forward; R: reverse.
sion at 72ºC for 1 min, followed by a final extension 
for 10 min at 72ºC. The PCR products were checked 
on 1% agarose gel electrophoresis, purified and auto-
matically sequenced in an ABI Prism Genetic Analyzer 
3100 automatic DNA sequencer (Applied Biosystems, 
Foster City, CA). All sequence variations were found on 
both strands and confirmed in a second PCR reaction. 
In silico analyses
All mutations were analyzed using NNSPLICE 0.9 and 
Human Splice Finder to evaluate if these mutations could 
create or disrupt splice sites or auxiliary (enhancer or si-
lencer) cis-splicing sequences. In addition, Polyphen-2 
and SIFT were utilized to predict the potential impact 
of non-synonymous amino acid substitutions (missense 
variants) on protein structure and activity.
RESULTS
Central precocious puberty
Sequencing of the TAC3 gene revealed a hetero-
zygous G to C transversion in coding nucleotide 187 
(c.187G>C) in a Brazilian girl with CPP. This mutation 
resulted in the substitution of alanine to proline at po-
sition 63 (p.A63P) of proneurokinin B (Table 3). The 
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for WT and G18D NK3R were not significantly diffe-
rent (10). 
The p.L58L (c.172C>T) and p.W275* variants 
were identified in a 20-year-old male. Physical examina-
tion showed right testes of 3.0 x 0.5 cm and left testes 
of 2.0 x 1.0 cm, and pubic hair Tanner stage III. Hor-
monal evaluation revealed low gonadotropins (RIA) 
(LH: 5 U/L; FSH: 9 U/L) and testosterone levels 
(RIA) (67 ng/dL). Similar cases of absent sexual devel-
opment in his family were mentioned, but the affected 
family members were not available for genetic analysis. 
Finally, the p.W275* variant in the homozygous 
state was identified in a 30-year-old male. Physical ex-
amination showed micropenis, right and left testes < 
2.0 x 1.5 cm, and pubic hair Tanner stage III. Hor-
monal evaluation revealed low basal gonadotropin 
(IFMA) (LH: < 0.6 U/L; FSH: < 1.0 U/L) and tes-
tosterone (IFMA) (35 ng/dL) levels. Familial segrega-
tion was not available. The mean (±SD) FSH/LH ratio 
of the three IHH patients with TACR3 variants was 
2.40 ± 1.33. 
Constitutional delay of growth and puberty
A new heterozygous variant in the TACR3 gene 
(c.1345G>T) was identified in a girl with CDGP. This 
variant resulted in the substitution of alanine to seri-
ne at position 449 (p.A449S) of NK3R (Table 3). The 
p.A449S variant was not identified in any subjects of 
the control group. Alanine at position 449 is not a con-
served residue among all species, and in silico analysis 
suggested that this variant neither altered a splicing site 
nor was deleterious to protein structure or function. 
The affected girl had pubertal onset at 13.4 years of 
age, and delayed bone age (11 years). Hormonal evalu-
ation revealed a pre-pubertal basal LH level (IFMA) 
0.6 U/L, and a low basal estrogen level (IFMA) 19 
pg/mL. The affected patient reported similar cases in 
her family, but these relatives were not available for seg-
regation analysis. 
Table 3. Variants of TAC3 and TACR3 genes identified in patients with idiopathic central pubertal disorders
Gene Nucleotide change Amino acid change Status Exon Phenotype
TAC3 c.187G>C p.A63P Heterozygous 3 Sporadic CPP
TACR3 c.53G>A p.G18D Heterozygous 1 Sporadic IHH
c.[172C>T(;) 824G>A] p.[L58L(;)W275*] Compound heterozygous 1 and 3 Familial IHH
c.824G>A p.W275* Homozygous 3 Familial IHH
c.1345G>T p.A449S Heterozygous 5 Familial CDGP
p.A63P variant was absent in the control population 
of 150 Brazilian patients. In silico analyses suggested 
that this variant does not alter the splicing sites, but it 
was predicted to be damaging to the protein (SIFT). 
However, the pathogenicity of this missense variant was 
not supported using the Polyphen-2 tool.
The affected girl had pubertal onset at 7 years of 
age. She had advanced bone age (11 years) and breast 
development pubertal stage Tanner 3. Hormonal eval-
uation revealed pubertal basal LH level (IFMA) of 1.2 
U/L, LH after acute GnRH stimulation (IFMA) of 
17.9 U/L, and pubertal basal estrogen level (IFMA) 
of 35.2 pg/mL. This girl was the only child of noncon-
sanguineous parents, and segregation analysis revealed 
that her mother, who had normal pubertal develop-
ment with menarche at age 12, was also heterozygous 
for the p.A63P variant, and that her father was homo-
zygous for the wild-type allele. 
Normosmic hypogonadotropic hypogonadism
Analysis of NK3R revealed three known distinct va-
riants p.G18D, p.L58L (c.172C>T) and p.W275* in 
three unrelated males with normosmic IHH (Table 3). 
All of them were found in heterozygous state, except 
p.W275*, which was identified in the homozygous sta-
te in one IHH patient, and in the heterozygous state 
in association with the p.L58L (c.172C>T) variant in 
another. All variants affected highly conserved residues, 
and were absent in the control group.
The p.G18D variant was identified in a 24-year-old 
male. Physical examination showed micropenis, right 
and left testes < 2.5 cm, and pubic hair Tanner stage 
II. Hormonal evaluation revealed low basal gonado-
tropin (IFMA) (LH: 0.8 U/L; FSH: 1.4 U/L), and 
testosterone (IFMA) (< 19 ng/dL) levels. In silico 
analyses predicted an impact of the p.G18D substi-
tution on protein structure using both PolyPhen and 
SIFT. Functional analysis of this variant demonstrated 
the NKB-stimulated fold increases in IP accumulation 
TAC3/TACR3 analysis in central pubertal disorders
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NK3R SNPS
Three polymorphisms previously described in the 
NK3R were identified in this cohort of patients. The 
p.K286R (c.857A>G) variant was identified in 0.9%, 
1.4%, and 2% of patients with CPP, normosmic IHH 
and CDGP, respectively, and it was not found in any 
control individual studied. The p.L291L (c.873A>G) 
variant was identified in 2.6%, 1.4% and 4% of patients 
with CPP, normosmic IHH and CDGP, respectively, 
and it was found in 4% of control individuals studied. 
The p.A449T (c.1345G>A) variant was identified in 
1.4% and 4% of patients with normosmic IHH and 
CDGP, respectively, and in 1% of control individuals 
studied. Polymorphism frequencies were similar to tho-
se previously reported (20).
DISCUSSION
Complex networks of inhibitory, stimulatory and per-
missive neuroendocrine factors are involved in the 
control of puberty onset. Loss-of-function mutations 
in the TAC3 and TACR3 genes result in normosmic 
IHH, characterized by an absence of pubertal develo-
pment and low circulating levels of LH and gonadal 
steroids (7-12). A recent study identified rare variants 
in genes associated with IHH in women with hypotha-
lamic amenorrhea, suggesting that these mutations may 
also contribute to the variable susceptibility of women 
to functional changes in GnRH secretion (21). The-
se observations provided compelling evidence for the 
role of rare variants in common multifactorial diseases 
(21). In this study, we analyzed the TAC3 and TACR3 
genes in a cohort of patients with central pubertal di-
sorders, including patients with central precocious pu-
berty, normosmic IHH, and constitutional delay of 
growth and puberty. We described five variants, one in 
NKB (p.A63P) and four in NK3R (p.G18D, p.L58L, 
p.W275* and p.A449S) in five unrelated patients with 
central pubertal disorders. All of these variants were ab-
sent in the control group, suggesting that they are not 
common polymorphisms in the Brazilian population. 
Activating mutations in KISS1 and KISS1R, a G 
protein-coupled receptor, were previously identified in 
Brazilian girls with CPP (18,19). Indeed, it is known 
that NKB is highly expressed in hypothalamic neurons 
that also express kisspeptin, and that NKB/NK3R are 
involved in the regulation of pubertal development 
(14). Hence, it is also reasonable to hypothesize that 
gain-of-function mutations in NKB or in NK3R, an-
other G protein-coupled receptor, might be identified 
in children with CPP. In this study, a new heterozy-
gous variant (p.A63P) in proneurokinin B was identi-
fied in a Brazilian girl with central precocious puberty 
who had pubertal onset at 7 years of age. TAC3 pre-
cursor mRNA contains seven exons, five of which are 
translated to form the preprotachykinin B peptide. This 
prepropeptide undergoes enzymatic cleavage to form 
proneurokinin B, then NKB. Loss-of-function muta-
tions in propeptides have been described in association 
with several phenotypes (22-24). Activating muta-
tions in propeptides are rare, and no functional studies 
identifying gain-of-function mutations in propeptides 
have been described to date. Comparative analysis of 
the amino acid sequence of neurokinin B showed that 
the alanine in position 63 is a conserved residue among 
primates. Nonetheless, this variant was not predicted to 
alter the splicing site, and the functional effects of this 
amino acid substitution were controversial using differ-
ent in silico algorithms.
Recent studies of humans with TAC3 and TACR3 
inactivating mutations provide compelling evidence for 
the involvement of neurokinin B signaling in human pu-
berty (7-12). In this study, we identified three distinct 
variants (p.G18D, p.L58L and p.W275*) in NK3R in 
three unrelated males with IHH who were previously 
described (10). All of them were heterozygous, ex-
cept for p.W275*. The p.W275* variant was the most 
prevalent variant identified in the TACR3 gene in this 
Brazilian cohort of patients, as well in the Gianetti and 
cols. (10) multicenter cohort. Furthermore, heterozy-
gous variants were found in two of three patients with 
TACR3 variants. Based on these findings, it is possible 
that our screening strategy failed to identify mutations 
in other regions. It is also possible that the heterozy-
gous mutations in TACR3 do not contribute to the 
pathogenesis of normosmic IHH, and that only the 
homozygous mutations have a causative role in IHH. 
Nevertheless, there are clear precedents for the asso-
ciation of normosmic IHH and Kallmann syndrome 
with heterozygous mutations in FGF8 and PROK2, 
which also encode secreted ligands (25-28). Another 
possibility is that heterozygous TACR3 mutations act 
in conjunction with mutations in other genes to cause 
normosmic IHH, a mechanism previously described in 
normosmic IHH and Kallmann syndrome (25,29-31). 
A high frequency of micropenis was detected in pa-
tients with TAC3/TACR3 variants, indicating NKB/
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NK3R signaling may be essential for the normal activa-
tion of the reproductive axis late in gestation (7,10-
12). All IHH patients with TACR3 variants were in the 
second decade of life or older, and showed unequivocal 
evidence of failure of pubertal progression with low cir-
culating sex steroids and prepubertal levels of circulat-
ing gonadotropins, and all of them presented with mi-
cropenis without cryptorchidism. Recently, dissociation 
between the very low basal LH and normal or nearly 
normal basal FSH levels was reported, suggesting the 
possibility of a specific neuroendocrine impairment 
and therefore impaired pulsatile delivery of GnRH in 
patients with alteration of NKB signaling (7,8,12). 
However, this hormonal profile was not observed in 
our study. IHH Brazilian patients with TACR3 variants 
showed similar FSH/LH ratios when compared to oth-
er IHH patients with mutations in GNRHR, KISS1R/
GNRH1, KISS1R/PROKR2, PROKR2, FGR1, FGF8, 
and in IHH patients with no identified genetic variants 
(data not shown).
Comparative analyses of the amino acid sequences of 
NK3R showed that these substitutions affected highly 
conserved residues among all species. In silico analy-
ses were performed, and they suggested that p.G18D 
variant could be damaging to protein structure, but in 
vitro studies revealed no significant differences in re-
ceptor signaling between wild type and mutant NK3R 
(10), suggesting that p.G18D variant is not responsible 
for the IHH phenotype.
Constitutional delay of growth and puberty is, at least 
in part, genetically determined. Although many genes 
may be involved with this condition, the inheritance pat-
terns suggest that there are still-to-be-uncovered single 
genes with major effects (32-34). We hypothesized that 
mutations in genes underlying IHH might contribute 
for the pathogenesis of this condition, with incomplete 
penetrance and/or variable expressivity (33). Recently, 
mutations in TAC3 or TACR3 genes in patients with 
IHH have been associated with high frequency of re-
versal IHH, a phenotype resembling constitutional de-
lay of growth and puberty (10). Although the NKB/
NK3R complex appear to be clear functional candidates 
for CDGP, no mutations in the coding region of these 
system have been described in the literature (33).
In this study, we identified a new heterozygous 
variant (p.A449S) in NK3R in a Brazilian girl with 
CDGP who had breast development at 13.4 years of 
age. Comparative analysis of the amino acid sequence 
of NK3R showed that alanine at position 449 is not a 
conserved residue among species. In silico analyses sug-
gested that this substitution did not alter splicing sites 
(NNSPLICE 0.9 and Human Splicing Finder), neither 
was damaging to the protein (PolyPhen and SIFT). 
Taken together, these data did not support a potential 
role for the p.A449S variant in the CDGP phenotype.
In conclusion, we described new rare variants in 
the NKB (p.A63P) and in the NK3R (p.A449S) in 
two girls, one with central precocious puberty and one 
with constitutional delay of growth and puberty. Our 
preliminary studies suggested that these two new vari-
ants do not seem to have a direct causative role in the 
precocious puberty and constitutional delay of growth 
and puberty phenotype. In addition, we identified 
three known distinct variants (p.G18D, p.L58L, and 
p.W275X) in the NK3R in three unrelated males with 
normosmic hypogonadotropic hypogonadism. Finally, 
we identified a positive association between TAC3 and 
TACR3 variants and a normosmic IHH phenotype, in-
dicating that NKB signaling is required for initiation 
and normal pubertal development.
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